Table 1 Demographic and clinical features of cases and controls
Feature | Cases n=32 (%) | Controls n=64 (%) | p |
|---|---|---|---|
Gender M | 23 (72%) | 46 (72%) | 0.8 |
Age (years)* | 45.7±7.6 | 45±9.9 | 0.6 |
BMI ≥25 | 15 (47%) | 22 (34%) | 0.3 |
< 25 | 17 (53%) | 42 (66%) | |
CDC stage A+B | 22 (69%) | 46 (72%) | 0.9 |
C | 10 (31%) | 18 (28%) | |
Years since HIV diagnosis* | 10.9±7.1 | 7.8±6.4 | 0.04 |
Risk factors for HIV infection | |||
IVDU | 8 (25%) | 10 (16%) | 0.3 |
MSM | 7 (22%) | 19 (30%) | |
Eterosexual | 16 (50%) | 35 (54%) | |
other | 1 (3%) | 0 | |
Arterial hypertension | 4 (12%) | 13 (20%) | 0.5 |
Current smokers | 18 (56%) | 36 (56%) | 0.8 |
Diabetes | 0 | 0 | |
Hypertriglyceridaemia | 7 (22%) | 17 (26%) | 0.8 |
Hypercholesterolaemia | 7 (22%) | 18 (28%) | 0.7 |
Alcohol abuse | 5 (16%) | 3 (5%) | 0.1 |
Familiarity for IHD | 10 (31%) | 23 (40%) | 0.8 |
Waist circumference (cm)* | 90.6±12.5 | 87.0±10.0 | 0.16 |
Hip circumference (cm)* | 97.3±10.4 | 96.0±6.9 | 0.5 |
Waist/hip ratio* | 0.93±0.07 | 0.90±0.07 | 0.05 |
Active drug abuse | 3 (9%) | 3 (5%) | 0.4 |
Methadone therapy | 2 (6%) | 3 (5%) | 1 |
Prophylaxis with cotrimoxazole | 3 (9%) | 8 (12%) | 0.7 |
Ongoing ART | 28 (87%) | 53 (83%) | 0.7 |
Type of ART | |||
-PI-based | 12 (37%) | 26 (41%) | 0.4 |
-NNRTI-based | 13 (41%) | 25 (39%) | |
-3 NRTI | 3 (9%) | 2 (3%) | |
HCV positive | 8 (25%) | 12 (19%) | 0.6 |
HBsAg positive | 1 (3%) | 1 (2%) | 1 |
Na (mEq/L)* | 139±3.2 | 139±3.9 | 1 |
K (mEq/L)* | 4,2±0.4 | 4,3±0.3 | 0.2 |
Ca (mg/dL)* | 9,2±0.6 | 9,1±0.5 | 0.4 |
CD4+ lymphocytes/mmc* | 501±214 | 490±264 | 0.8 |
HIVRNA (cp/mL) | |||
<50 | 23 (72%) | 45 (70%) | 0.9 |
≥50 | 9 (28%) | 19 (30%) | |
QTc interval (ms)* | 475±33 | 401±23 | <0.0001 |
Ectopic ventricular beats | 13 (41%) | 17 (26%) | 0.2 |
Ectopic supraventricular beats | 14 (44%) | 30 (47%) | 0.9 |